Literature DB >> 29234152

LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer.

Haoyu Zhou1, Zhihua Sun2, Songwei Li3, Xiaofeng Wang4, Xuejun Zhou5.   

Abstract

Long non-coding RNAs (lncRNAs) have been demonstrated to be critical regulators in tumorigenesis. LncRNA SPRY4-IT1 has been identified as critical regulator for hepatocellular carcinoma and ovarian cancer. However, the potential role and clinical value of SPRY4-IT1 in human thyroid cancer (TC) still remain unclear and need to be uncovered. Our current study was aimed to ascertain the biological role of expression of SPRY4-IT1 in TC tissues and cells. Our findings revealed that the level of SPRY4-IT1 was significantly upregulated in TC tissues and cell lines, which was correlated with poor prognosis. And cellular experiments exhibited that silenced SPRY4-IT1 inhibited the proliferative and migratory abilities of TC cells. Mechanism assays noted that silenced SPRY4-IT1 could increase the levels of transforming growth factor-β1 (TGF-β1) and p-Smad2/3 and function mediated by si-SPRY4-IT1 could be rescued by the interference of TGF-β1. Generally speaking, these findings elucidated that SPRY4-IT1 might become a novel prognostic factor in the clinical behaviors of TC patients and participated in the progression of TC through targeting TGF-β/Smad signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29234152     DOI: 10.1038/s41417-017-0003-0

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  12 in total

1.  Upregulation of the long non-coding RNA FOXD2-AS1 is correlated with tumor progression and metastasis in papillary thyroid cancer.

Authors:  Hongqiang Li; Qicai Han; Yali Chen; Xiaolong Chen; Runsheng Ma; Qungang Chang; Detao Yin
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

2.  NPSR1-AS1 activates the MAPK pathway to facilitate thyroid cancer cell malignant behaviors via recruiting ELAVL1 to stabilize NPSR1 mRNA.

Authors:  Tiangen Ni; Dan Guo; Ling Tan; Zhesi Xiao; Yanjie Shi
Journal:  Cell Cycle       Date:  2022-01-14       Impact factor: 4.534

Review 3.  The Role of Long Non-Coding RNAs in Thyroid Cancer.

Authors:  Xuejiao Peng; Kun Zhang; Li Ma; Junfeng Xu; Weiqin Chang
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

Review 4.  TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.

Authors:  Yang Hao; David Baker; Peter Ten Dijke
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

5.  LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.

Authors:  Wen Yang; Zhikun Zheng; Pengfei Yi; Shi Wang; Ning Zhang; Jie Ming; Jie Tan; Hui Guo
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

6.  Regulation of TGFβ/SMAD signaling by long non-coding RNAs in different cancers: Dark Knight in the Castle of molecular oncology.

Authors:  Aima Adylova; Auyezova Ardak Mukhanbetzhanovna; Rukset Attar; Ishmuratova Margarita Yulaevna; Ammad Ahmad Farooqi
Journal:  Noncoding RNA Res       Date:  2021-01-07

7.  lncRNA RUNDC3A-AS1 Regulates Proliferation and Apoptosis of Thyroid Cancer Cells via the miR-151b/SNRPB Axis.

Authors:  Yan Deng; Jie Wu; Xin Li
Journal:  Int J Endocrinol       Date:  2022-02-22       Impact factor: 3.257

8.  Long non-coding RNA SPRY4-IT1 promotes cell proliferation and invasion by regulation of Cdc20 in pancreatic cancer cells.

Authors:  Wenhao Guo; Kunhong Zhong; Heng Wei; Chunlai Nie; Zhu Yuan
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

Review 9.  Long non-coding RNAs and TGF-β signaling in cancer.

Authors:  Panagiotis Papoutsoglou; Aristidis Moustakas
Journal:  Cancer Sci       Date:  2020-06-17       Impact factor: 6.716

10.  Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database.

Authors:  Hai-Mei Wang; Hui-Jie Li; Jun-Zhen Chen; Ke Pei; Qian Zhang; Zhai-Dong Liu; Yuan-Fu Qi
Journal:  Biomed Res Int       Date:  2020-11-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.